PME:ASXPro Medicus, Ltd. Analysis

Pro Medicus (PME) is trading at AUD 164, well above its DCF fair value of AUD 37.7 and its 30‑day simple moving average of 142.7, indicating a heavily overvalued market price. Technicals show an RSI of 74 (overbought) and a bullish MACD histogram of 2.77, while the stock sits just below the identified resistance of 167.8. Recent contract renewals – a $16 m five‑year deal with Ohio State University and a $90 m seven‑year agreement with Beth Israel Lahey Health – have fueled a short‑term rally and contributed to the “Extreme Greed” sentiment signal. However, the price‑to‑earnings ratio of 72.9 dwarfs the industry average of 24.8, and the upside/downside estimate suggests only a modest 10 % upside potential.
Fundamentally, PME delivers exceptional profitability with a profit margin of 97.6 %, operating margin of 72.7 % and ROE of 76.8 %, supported by a strong cash position of AUD 221.8 m and low debt. The dividend yield of 0.39 % is underpinned by a modest payout ratio of 24.5 %, making the dividend sustainable. Volatility remains high at 48 % over 30 days and beta is above 1, indicating market‑wide risk, while liquidity appears adequate given increasing volume trends. Overall, the stock’s valuation is stretched, but its growth trajectory and contract pipeline justify a cautious, medium‑term buying stance.